Dr. Zingman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
AIDS Center
Bronx, NY 10467Phone+1 718-920-2647Fax+1 718-405-0610
Education & Training
- Boston University Medical CenterFellowship, Infectious Disease, 1988 - 1991
- Boston University Medical CenterResidency, Internal Medicine, 1985 - 1988
- New York University School of MedicineClass of 1985
Certifications & Licensure
- null, NY 1991 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
Publications & Presentations
PubMed
- HealthCall: Smartphone Enhancement of Brief Interventions to Improve HIV Medication Adherence Among Patients in HIV Care.Justin Knox, Efrat Aharonovich, Barry S Zingman, Malka Stohl, Claire Walsh
AIDS and Behavior. 2024-06-01 - Clinical Presentations and Treatment Outcomes of Mycoplasma genitalium Infections at a Large New York City Health Care System.Caroline E Mullis, Kerry A Marlow, Aloke Maity, Melissa Fazzari, Barry S Zingman
Sexually Transmitted Diseases. 2024-03-01 - Economic Cost of the HealthCall Smartphone Intervention to Reduce Heavy Alcohol Drinking in Adults With HIV.Laura E Starbird, Sarah Gutkind, Paul Teixeira, Sean Murphy, Efrat Aharonovich
Journal of Studies on Alcohol and Drugs. 2023-11-01
Journal Articles
- Remdesivir for the Treatment of Covid-19 — Final ReportAneesh K Mehta, Barry S Zingman, Andre C Kalil, Helen Y Chu, Robert W Finberg, Kerry Dierberg, Victor Tapson, Lanny Hsieh, Thomas F Patterson, Daniel A Sweeney, Willia..., The New England Journal of Medicine
Press Mentions
- Montefiore AIDS Center Awarded $1 Million to Curb Disproportionate Impact of HIV on Women of Color in the BronxOctober 8th, 2024
- Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-Risk COVID-19 Outpatient StudyMay 9th, 2022
- Montefiore/Einstein Lead Drug Trial on COVID-19 Antiviral Drug, Merck, Approved in the UKNovember 8th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: